Implementation of a new guideline in cardiovascular secondary preventive care: Subanalysis of a randomized controlled trial

BMC Cardiovascular Disorders

Volumn 16, Issue 1, 2016, Pages

  Jakobsson, Stina ^a,b   Huber, Daniel ^a   Björklund, Fredrik ^a   Mooe, Thomas ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b NONE   (Sweden)

Author keywords

Acute coronary syndrome; Cardiovascular disease; Myocardial infarction; Randomized controlled trial; Secondary prevention; Stroke; Transient ischemic attack

Indexed keywords

ATORVASTATIN PLUS EZETIMIBE; EZETIMIBE PLUS ROSUVASTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HEALTH CARE; SWEDEN; TELEHEALTH; TRANSIENT ISCHEMIC ATTACK; BLOOD; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; COUNSELING; DYSLIPIDEMIAS; NURSING; PROCEDURES; PROTOCOL COMPLIANCE; RISK FACTOR; SECONDARY PREVENTION; STANDARDS; TELEPHONE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; COUNSELING; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SECONDARY PREVENTION; SWEDEN; TELEPHONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85007479631     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-016-0252-0     Document Type: Article

References (28)

1. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke. 2007;38(6):1881-5. doi:10.1161/STROKEAHA.106.475525.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. doi:10.1093/eurheartj/eht151.
3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-701. doi:10.1093/eurheartj/ehs092.
4. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-236. doi:10.1161/STR.0000000000000024.
5. Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458-73. doi:10.1161/CIR.0b013e318235eb4d.
6. Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, et al. Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol. 2012;19(3):541-50. doi:10.1177/1741826711407705.
7. Heidrich J, Behrens T, Raspe F, Keil U. Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany. Eur J Cardiovasc Prev Rehabil. 2005;12(6):521-9.
8. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract. 2002;19(6):596-604.
9. Alvarez-Sabin J, Quintana M, Hernandez-Presa MA, Alvarez C, Chaves J, Ribo M. Therapeutic interventions and success in risk factor control for secondary prevention of stroke. J Stroke Cerebrovasc Dis. 2009;18(6):460-5. doi:10.1016/j.jstrokecerebrovasdis.2009.01.014.
10. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-9. doi:10.1001/jama.295.2.180.
11. Saposnik G, Goodman SG, Leiter LA, Yan RT, Fitchett DH, Bayer NH, et al. Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals? Stroke. 2009;40(4):1417-24. doi:10.1161/STROKEAHA.108.533018.
12. Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2015. doi:10.1177/2047487315569401.
13. Buckley BS, Byrne MC, Smith SM. Service organisation for the secondary prevention of ischaemic heart disease in primary care. Cochrane Database Syst Rev. 2010;3:CD006772. doi:10.1002/14651858.CD006772.pub2.
14. Lager KE, Mistri AK, Khunti K, Haunton VJ, Sett AK, Wilson AD. Interventions for improving modifiable risk factor control in the secondary prevention of stroke. Cochrane Database Syst Rev. 2014;5:CD009103. doi:10.1002/14651858.CD009103.pub2.
15. McAlister FA, Majumdar SR, Padwal RS, Fradette M, Thompson A, Buck B, et al. Case management for blood pressure and lipid level control after minor stroke: PREVENTION randomized controlled trial. CMAJ. 2014;186(8):577-84. doi:10.1503/cmaj.140053.
16. Neubeck L, Redfern J, Fernandez R, Briffa T, Bauman A, Freedman SB. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16(3):281-9. doi:10.1097/HJR.0b013e32832a4e7a.
17. Mooe T, Bjorklund F, Graipe A, Huber D, Jakobsson S, Kajermo U, et al. The Nurse-Based Age Independent Intervention to Limit Evolution of Disease After Acute Coronary Syndrome (NAILED ACS) Risk Factor Trial: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2014;3(3):e42. doi:10.2196/resprot.3466.
18. Mooe T, Bergstrom L, Irewall AL, Ogren J. The NAILED stroke risk factor trial (nurse based age independent intervention to limit evolution of disease after stroke): study protocol for a randomized controlled trial. Trials. 2013;14:5. doi:10.1186/1745-6215-14-5.
19. Shojania KG, Ranji SR, McDonald KM, Grimshaw JM, Sundaram V, Rushakoff RJ, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA. 2006;296(4):427-40. doi:10.1001/jama.296.4.427.
20. Lear SA, Spinelli JJ, Linden W, Brozic A, Kiess M, Frohlich JJ, et al. The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial. Am Heart J. 2006;152(2):333-9. doi:10.1016/j.ahj.2005.12.023.
21. Redfern J, Briffa T, Ellis E, Freedman SB. Choice of secondary prevention improves risk factors after acute coronary syndrome: 1-year follow-up of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) randomised controlled trial. Heart. 2009;95(6):468-75. doi:10.1136/hrt.2008.150870.
22. Vale MJ, Jelinek MV, Best JD, Dart AM, Grigg LE, Hare DL, et al. Coaching patients On Achieving Cardiovascular Health (COACH): a multicenter randomized trial in patients with coronary heart disease. Arch Intern Med. 2003;163(22):2775-83. doi:10.1001/archinte.163.22.2775.
23. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate-or highintensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870-82. doi:10.1001/jama.2014.4030.
24. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. doi:10.1056/NEJMoa1410489.
25. Graham IM, Stewart M, Hertog MG. Cardiovascular Round Table Task F. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil. 2006;13(5):839-45. doi:10.1097/01.hjr.0000219112.02544.24.
26. Hibble A, Kanka D, Pencheon D, Pooles F. Guidelines in general practice: the new Tower of Babel? BMJ. 1998;317(7162):862-3.
27. Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166(3):597-603. doi:10.1016/j.ahj.2013.06.004.
28. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526-34. doi:10.7326/0003-4819-158-7-201304020-00004.